Galderma and Spirig, two specialists of dermatology products have entered into a definitive agreement under which Galderma will acquire Spirig.
“With this acquisition, Galderma will become the dermatology market leader in Switzerland, our home country. Additionally, with our global presence, we will be able to make Spirig’s outstanding products available to a larger number of patients around the world,” said Humberto C. Antunes, Chief Executive Officer of Galderma.
Spirig is the leader in dermatology in Switzerland. With 390 employees in total, Spirig generated sales of CHF 98.4 million in 2011. The company’s products treat conditions such as solar damage and skin barrier function impairment.
As per Galderma, the company achieved a turnover of approximately CHF 1.6 billion in 2011, in 70 countries.
Furthermore, Galderma intends to utilize Spirig’s Egerkingen location as headquarters to its Swiss market operations and as a center-of-excellence. The global corporate headquarters of Galderma remain in Lausanne. The transaction is expected to close in early 2013, subject to the fulfilment of customary closing conditions.